Key facts
- Arktus Therapeutics’s last known valuation is $14.8M (Jul 2025).
- It has raised $7.4M; the latest was Early Stage VC ($4.5M) in Jul 2025.
- Notable investors include Mirai Cross, Kyoto University Innovation Capital, Leave a Nest Capital, Sagin Capital & Consulting, MUFG Bank — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Arktus Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Arktus Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arktus Therapeutics
Developer of regenerative medical technology designed for knee cartilage regeneration. The company offers a combination of induced pluripotent stem cell research knowledge and three-dimensional printing technology to create a cell-derived cartilage implant that allows for a personalized treatment based on the individual's condition, enabling patients to recover their natural movement and experience a healthier life beyond the limitations of previous methods.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2023
- Website
- arktustx.com/
- Ownership
- Privately Held (backing)
Arktus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arktus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arktus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.